BNP Paribas Financial Markets Has $1.16 Million Stock Position in Masimo Co. (NASDAQ:MASI)

BNP Paribas Financial Markets cut its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 64.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,020 shares of the medical equipment provider's stock after selling 12,962 shares during the quarter. BNP Paribas Financial Markets' holdings in Masimo were worth $1,160,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after buying an additional 1,340,836 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Masimo by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after buying an additional 66,215 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after buying an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Masimo by 119.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock valued at $286,823,000 after buying an additional 943,001 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its stake in shares of Masimo by 8.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock valued at $274,791,000 after buying an additional 135,888 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Masimo Trading Up 0.1%

MASI stock traded up $0.22 during midday trading on Friday, reaching $150.13. The stock had a trading volume of 311,070 shares, compared to its average volume of 651,566. The business has a fifty day simple moving average of $158.42 and a two-hundred day simple moving average of $167.42. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $8.14 billion, a price-to-earnings ratio of 103.54 and a beta of 1.23. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company's revenue for the quarter was down 24.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 EPS. As a group, research analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,053 shares of company stock worth $6,998,565. 16.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Wells Fargo & Company lowered their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Raymond James lowered their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $200.00 target price (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Finally, BTIG Research set a $193.00 target price on Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.